|
Originally published In Press as doi:10.1074/jbc.C000385200 on August 4, 2000
J. Biol. Chem., Vol. 275, Issue 41, 31559-31562, October 13, 2000
ACCELERATED PUBLICATION
Active Aminoacyl-tRNA Synthetases Are Present in Nuclei as a High
Molecular Weight Multienzyme Complex*
Lubov
Nathanson and
Murray P.
Deutscher
From the Department of Biochemistry and Molecular Biology,
University of Miami School of Medicine,
Miami, Florida 33136
Received for publication, June 15, 2000, and in revised form, August 3, 2000
 |
ABSTRACT |
Recent studies suggest that aminoacylation of
tRNA may play an important role in the transport of these molecules
from the nucleus to the cytoplasm. However, there is almost no
information regarding the status of active aminoacyl-tRNA synthetases
within the nuclei of eukaryotic cells. Here we show that at least 13 active aminoacyl-tRNA synthetases are present in purified nuclei of
both Chinese hamster ovary and rabbit kidney cells, although their
steady-state levels represent only a small percentage of those found in
the cytoplasm. Most interestingly, all the nuclear aminoacyl-tRNA
synthetases examined can be isolated as part of a multienzyme complex
that is more stable, and consequently larger, than the comparable
complex isolated from the cytoplasm. These data directly demonstrate
the presence of active aminoacyl-tRNA synthetases in mammalian cell
nuclei. Moreover, their unexpected structural organization raises
important questions about the functional significance of these
multienzyme complexes and whether they might play a more direct role in
nuclear to cytoplasmic transport of tRNAs.
 |
INTRODUCTION |
Aminoacyl-tRNA synthetases catalyze the first step in protein
biosynthesis, the attachment of an amino acid to its cognate tRNA (1).
In higher eukaryotes the aminoacyl-tRNA synthetases are part of a
highly organized translation system (2, 3) and can be isolated from
cells as a high molecular weight multienzyme complex (4-7). The number
of synthetases in this fragile complex varies in different
laboratories, but a stable core of nine of these enzymes plus three
non-synthetase proteins can be isolated reproducibly (5-7). Evidence
has accumulated that the multienzyme synthetase complex reflects
associations among these proteins that pre-exist in vivo
(8-10).
Despite the fact that protein synthesis takes place in the cytoplasm of
eukaryotic cells, several studies suggested that aminoacyl-tRNA synthetases might also be present in nuclei. Thus, in early work, aminoacyl-tRNA synthetase activities could be detected in crude nuclear
fractions (11, 12); however, it could be argued that these activities
were due to cytoplasmic adherence to the outer nuclear surface.
Aminoacyl-tRNA synthetases, as well as elongation factor 1 (EF1),1 also could be
detected in nuclei by immunochemical methods (13-16). However, these
studies provided no information as to whether the nuclear-localized
synthetases were active. Nuclear localization was also suggested by the
identification of possible nuclear localization signals in yeast
aminoacyl-tRNA synthetases (17).
Recently, nuclear aminoacyl-tRNA synthetases have attracted
considerable interest because of their potential involvement in nuclear
to cytoplasmic transport of tRNA. Exclusion of defective tRNA from the
cytoplasm was shown to be due to nuclear proofreading, and it was
proposed that aminoacylation of tRNA serves as this proofreading step
(18-20). While there is still some discussion whether aminoacylation
or binding to the nuclear export receptor, exportin-t, is actually
responsible for proofreading, there is agreement that nuclear
aminoacylation increases tRNA export efficiency (21, 22).
In light of these findings, it was of interest to carefully examine
nuclei for the presence of active aminoacyl-tRNA synthetases and to
determine what percentage of total cellular synthetase activity might
reside in the nucleus. The data reported here directly demonstrate that
active aminoacyl-tRNA synthetases are present in the nuclei of two
different mammalian cell lines. Most importantly, we find that the
nuclear aminoacyl-tRNA synthetases are organized into a high molecular
weight, multienzyme complex that is even more stable than the complex
present in the cytoplasm.
 |
EXPERIMENTAL PROCEDURES |
Materials--
3H-Labeled arginine, proline,
leucine, glycine, histidine, valine, and 14C-labeled
isoleucine, phenylalanine, lysine, and threonine were purchased from
NEN Life Science Products. 3H-labeled aspartic acid,
serine, and tryptophan were from Amersham Pharmacia Biotech.
CompleteTM Protease Inhibitor Cocktail Tablets were
from Roche Molecular Biochemicals. Cell culture reagents were from Life
Technologies, Inc. Rabbit kidney (LCC-RK1) cells and Chinese hamster
ovary (CRL-1781) cells were obtained from the American Type Culture
Collection. Rabbit liver tRNA was prepared as described
previously (2).
Cell Culture--
Rabbit kidney cells were cultured as described
previously (8). CHO cells were maintained as monolayers in minimum essential medium containing ribonucleosides and
deoxyribonucleosides and supplemented with 10% fetal bovine serum.
Cells were cultured in Nunc flasks at 37 °C in air containing 5%
CO2 and were transferred every 2-3 days. Cells were
harvested at 80-90% of confluence by incubation with warm
phosphate-buffered saline (PBS) supplemented with 0.53 mM
EDTA. The cells were washed twice with ice-cold PBS, resuspended in
sucrose buffer (10 mM Tris-HCl, pH 8.0, containing 0.32 M sucrose, 3 mM CaCl2, 2 mM magnesium acetate, 0.1 mM EDTA, and protease
inhibitors (1 tablet/50 ml of solution)) and counted in a
hemacytometer. The cell suspension was immediately supplemented with an
equal volume of the same buffer containing 1% Nonidet P-40 for
aminoacyl-tRNA synthetase assays.
Preparation of S10 Supernatant (Cytoplasmic)
Fractions--
After harvesting and washing in PBS, the rabbit kidney
cell pellet was quickly frozen in an ethanol-dry ice bath and thawed in
Buffer A (20 mM HEPES-KOH buffer, pH 7.4, containing 0.5 mM spermine, 130 mM KCl, 1% thiodiglycol, 0.5 mM EDTA, 2 mM CaCl2, and protease
inhibitors). The cells in this buffer were incubated on ice for 15 min
with occasional stirring. The crude lysate, prepared in this manner,
was centrifuged at 10,000 × g, and the supernatant
fraction was used for gel filtration. The cytoplasmic fraction of CHO
cells was prepared in the same way except that the cells were thawed in
the sucrose buffer.
Nuclear Isolation--
After harvesting, the frozen pellet of
rabbit kidney cells was thawed in ice-cold Buffer A containing 0.1%
Nonidet P-40. Cells at a concentration of ~2 × 107
cells/ml were disrupted in a Dounce-type tissue homogenizer (Wheaton) using five strokes of the B pestle. The cell lysate was spun down for 5 min at 1000 × g, and the same procedure (resuspension,
homogenization and centrifugation) was repeated with the pellet. The
final crude nuclear pellet was suspended in sucrose buffer containing
0.5% Nonidet P-40. This suspension was mixed with an equal volume of 10 mM Tris-HCl, pH 8.0, containing 2.2 M
sucrose, 5 mM magnesium acetate, and 0.1 mM
EDTA. Purified nuclei were collected by centrifugation through the
sucrose solution using 2.2 M sucrose as a cushion (23).
The same procedure was used for isolation of CHO cell nuclei except
that the cell pellet was thawed directly in sucrose buffer, and after
five strokes with the Dounce homogenizer the procedure described in
Ref. 23 was followed directly. Sucrose at 1.9 M was used
for the cushion.
Aminoacylation Assay--
Aminoacyl-tRNA synthetase activity
assays were carried out at 37 °C in reaction mixtures containing:
250 mM Tris-HCl, pH 7.5, 5 mM ATP, 5 mM MgCl2, 0.2 mM EDTA, 0.2 mg/ml
bovine serum albumin, 1.5 mg/ml rabbit liver tRNA, 0.1 mM
3H- or 14C-labeled amino acid (~20-100
cpm/pmol), and sufficient cell extract, nuclear extract, or column
fraction to measure significant synthetase activity within the linear
range. Reactions were stopped by the addition of 10% trichloroacetic
acid containing 0.5% casamino acids (Difco). Aminoacyl-tRNA
precipitates were collected and counted as described previously
(4). In this study we did not attempt to optimize the assay conditions
for each amino acid in terms of pH, ionic strength, cation
requirements, etc. Rather, the same assay conditions were used for
measuring all of the aminoacyl-tRNA synthetase activities.
Immunobloting Procedure--
After electrophoresis on 8%
polyacrylamide gels (24, 25), proteins were transferred to a
polyvinylidene difluoride membrane in Tris-glycine buffer (0.375 M Tris, 0.192 M glycine, 20% methanol). Blocking of the membrane was with a 5% solution of nonfat milk in TBS
buffer (10 mM Tris-HCl, pH 8.0, 0.15 M NaCl)
for 2 h at room temperature. The membrane was then treated with
monoclonal antibody F7 directed against rabbit arginyl-tRNA synthetase
(8) in TBS buffer supplemented with 0.2% Tween 20 (2 µg of
antibody/10 ml of buffer) overnight at 4 °C with shaking.
Visualization of the protein bands followed the ECL Western blotting
protocol (Amersham Pharmacia Biotech) using, as the secondary antibody,
goat anti-mouse IgG conjugated with horseradish peroxidase.
 |
RESULTS AND DISCUSSION |
Purity of Nuclei--
To ensure that the purified nuclei were free
of contamination, nuclei at each step of the purification procedure
were stained with azure C and examined by light microscopy (26).
Cytoplasmic adherence was clearly visible in crude nuclei, but after
purification, no cytoplasmic contamination was evident.
Moreover, assay of the cytoplasmic marker enzyme, lactate
dehydrogenase, confirmed that the purified nuclei were devoid of
cytoplasm. Thus, CHO and rabbit kidney cell extracts contained
approximately 600 and 300 units of lactate dehydrogenase
activity/106 cells, respectively (1 unit = 1 µmol
NADH formed per min). Lactate dehydrogenase activity in nuclei from
each of these sources was below the level of detection (25 millinunits
per 106 nuclei) or <0.01%.
Purified nuclei were also assayed for the possibility of mitochondrial
contamination. The amounts of citrate synthase and cytochrome
c oxidase in nuclei from each cell were again below the
level of detection representing <0.2% of that present in
detergent-treated cell extracts.
Most importantly, mammalian cell cytoplasmic extracts are known to
contain two forms of arginyl-tRNA synthetase, one present in the
multienzyme complex and one free form (27, 28). As will be shown below,
the low molecular weight form is absent from the nuclear preparations.
These data all support the conclusion that the nuclear preparations
used for these studies were free of contamination.
Quantitation of Nuclear Aminoacyl-tRNA Synthetase
Activity--
Total cellular aminoacyl-tRNA synthetase activity,
determined by assay of lysates prepared by Nonidet P-40 treatment, and total nuclear activity, determined in nuclear lysates, were compared for the two cell lines (Table I). Nuclear
aminoacyl-tRNA synthetase activity clearly was present in both cells.
However, in each case, it represented only a small percentage of the
total cellular activity, amounting to about 2-3% for the CHO cells
and less than 1% for the rabbit kidney cells.
View this table:
[in this window]
[in a new window]
|
Table I
Activities of aminoacyl-tRNA synthetases in nuclear fractions of CHO
and rabbit kidney cells
Cells were prepared as described under "Experimental Procedures."
Nuclei after isolation were resuspended in sucrose buffer and counted
in a hemacytometer. Approximately 4 × 104 cells or 2 × 106 to 8 × 106 nuclei were assayed for
aminoacyl-tRNA activities for 2 min. A unit of activity corresponds to
the formation of 1 nmol of aminoacyl-tRNA/min at 37 °C.
|
|
There are several possible explanations for the higher percentage of
nuclear activity in CHO cells compared with rabbit kidney cells. One
reason may be the difference in growth rate of the two cells (10 h
doubling time for CHO cells and 45 h for rabbit kidney cells). The
higher growth rate for CHO cells would necessitate a greater flux of
tRNA from nucleus to cytoplasm and consequently an increased
requirement for nuclear aminoacyl-tRNA synthetases. Second,
rabbit kidney cells are much more difficult to disrupt, and isolation
of their nuclei also requires a greater period of time. This may result
in increased nuclear breakage and/or leakage of nuclear synthetases
during the isolation procedure. Nevertheless, these data show that
active aminoacyl-tRNA synthetases are present in mammalian nuclei,
although at a relatively low level.
Structural Organization of Nuclear Aminoacyl-tRNA
Synthetases--
Many cytoplasmic aminoacyl-tRNA synthetases are found
in extracts as part of a multienzyme complex (4-7). It was of
interest, therefore, to ascertain whether the corresponding nuclear
enzymes might also be part of a complex or whether complex formation is only a cytoplasmic phenomenon. For this purpose, the size distribution of 13 aminoacyl-tRNA synthetases in cytoplasmic and nuclear extracts were examined by gel filtration on Sephacryl S-400. Since very similar
patterns were obtained for rabbit kidney and CHO cell extracts, only
those relating to CHO cells will be presented here. Prior to
chromatography, the nuclear fraction was concentrated so that the
amounts of nuclear and cytoplasmic synthetase activities loaded on the
column would be more comparable. Assay conditions (amount of column
fraction and time of assay) were also adjusted to ensure that the
levels of nuclear and cytoplasmic activities would be similar.
Treatment of the rabbit kidney nuclear extract with DNase I (1200 units/ml for 90 min) did not alter the elution profiles (data not shown).
The size distribution of cytoplasmic synthetase activities is presented
in Fig. 1, A and B.
Of the 13 activities assayed, aminoacyl-tRNA synthetases specific for
arginine, aspartic acid, isoleucine, leucine, lysine, and proline
co-eluted as a high molecular weight peak with an apparent molecular
mass of ~106 Da (Fig. 1A), in complete
agreement with the known composition of the stable core of the
multienzyme complex from CHO cells (13). Arginyl-tRNA synthetase also
had a second peak of activity in the low molecular weight region, as
expected (27, 28). Of the seven other synthetase activities measured,
all except valyl-tRNA synthetase eluted primarily as free proteins,
although in some cases shoulders of higher molecular weight forms were
also observed (Fig. 1B). Valyl-tRNA synthetase is known to
form a complex with EF-1H (29) resulting in a higher molecular weight
entity, but one that is clearly smaller than the multienzyme synthetase
complex (Fig. 1B).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 1.
Gel filtration on Sephacryl S400 of the
cytoplasmic and nuclear fractions of CHO cells. Cystoplasmic
fraction was prepared as described under "Experimental Procedures."
The nuclear fraction was resuspended in the protein extraction buffer
(20 mM Tris-HCl, pH 8.0, 10% glycerol (v/v), 0.4 M NaCl, 1 mM dithiothreitol, and 1 unit/µl RNasin (Promega). After 1 h of shaking at 4 °C, the
nuclear fraction was centrifuged at 18,000 × g for 15 min. The supernatant fraction, containing more than 90% of the nuclear
aminoacyl-tRNA synthetase activities, was concentrated by
ultrafiltration on a Diaflo YM30 membrane. The cytoplasmic fraction
(1.3-1.5 mg) or the concentrated nuclear extract (5.5-6.0 mg), 170 µl of each, was applied to a column (0.7 × 50 cm) of Sephacryl
S400 equilibrated with 50 mM Tris-HCl, pH 7.5, 10%
glycerol (v/v), 0.2 mM dithiothreitol, 0.2 mM EDTA, and 100 mM NaCl and eluted at a flow
rate of 2.5 ml/h. Fractions of 0.5 ml were collected. Cytoplasmic
fractions (20 µl) were assayed for 10 min, and nuclear fractions (60 µl) were assayed for 20 min. A and B,
cytoplasmic fraction; C and D, nuclear fraction.
A and C, aminoacyl-tRNA synthetases specific for
arginine ( ), aspartic acid ( ), isoleucine ( ), leucine ( ),
lysine (+), proline ( ); B and D,
aminoacyl-tRNA synthetases specific for glycine ( ), histidine (×),
phenylalanine ( ), serine (open box with slash), threonine
( ), tryptophan ( ), valine ( ). Arrows indicate the
elution volumes of the size markers (blue dextran (2 × 103 kDa), thyroglobulin (650 kDa), and catalase (250 kDa)
from left to right) determined in a separate run.
According to the manufacturer, the exclusion limit of Sephacryl S400 is
8 × 106. Based on extrapolation from the other
standards, Vo would be at 6.3 ml.
|
|
The elution profiles of the nuclear aminoacyl-tRNA synthetases are
presented in Fig. 1, C and D. Surprisingly, not
only do the nuclear activities elute as high molecular weight proteins, but more of them do so. The synthetases that normally are found in the
cytoplasmic multienzyme complex (Fig. 1A), also co-elute in
the nuclear fraction, strongly suggesting that they exist as a
multienzyme complex in nuclei as well. Moreover, the enzymes that are
predominantly found as free forms in the cytoplasm (Fig. 1B)
elute as much larger entities in the nuclear extract (Fig. 1D), with at least a portion of all of them eluting as part
of the complex. As a consequence, the nuclear complex is considerably larger than its cytoplasmic counterpart (~2.5 × 106
compared with ~1 × 106 Da).
Additional evidence for the nuclear multienzyme complex comes from
immunoprecipitation experiments. Using the monoclonal antibodies against glutamyl-tRNA synthetase (8), we were able to
co-immunoprecipitate at least three other aminoacyl-tRNA synthetases
(data not shown). These data support the conclusion that the nuclear
aminoacyl-tRNA synthetases are physically associated.
Interestingly, the low molecular weight form of arginyl-tRNA
synthetase, which is prevalent in the cytoplasmic extract (Fig. 1A), is not seen in the nuclear extract (Fig.
1C). Furthermore, Western immunoblot analysis of proteins
from rabbit kidney nuclei failed to detect any low molecular weight
arginyl-tRNA synthetase (Fig. 2). These
data confirm the purity of the nuclear preparation and indicate that
this form of arginyl-tRNA synthetase is exclusively a cytoplasmic
component. It was postulated that the low molecular weight form of
arginyl-tRNA synthetase provides arginyl-tRNA for the N-terminal
arginylation of proteins targeted for degradation by the
ubiquitin-dependent pathway (30). The present data
suggest that this process is located only in the cytoplasm.

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 2.
Low molecular weight arginyl-tRNA synthetase
is not present in the nuclear fraction of rabbit kidney cells.
Cytoplasmic fraction was prepared as described under "Experimental
Procedures." After isolation, nuclei were resuspended in sucrose
buffer. Immunobloting was carried out with monoclonal antibody F7 (8).
The film was overexposed to ascertain the absence of the band
corresponding to the low molecular weight form of the arginyl-tRNA
synthetase in the nuclear fraction. Lane 1, nuclear
fraction, corresponding to 150 µg of total protein; lane
2, cytoplasmic fraction, corresponding to 20 µg of total
protein. The values on the left (in kilodaltons) indicate
the position of the size standards.
|
|
Multienzyme complexes of aminoacyl-tRNA synthetases have been isolated
from a variety of higher eukaryotic cells (5-7). However, the
composition of these complexes often varies. A relatively stable
complex of nine aminoacyl-tRNA synthetases plus three non-synthetase proteins can be isolated reproducibly, but smaller and larger complexes
have also been isolated. This has led to some uncertainty as to whether
the multienzyme complex only contains nine synthetases or whether that
form of the complex simply represents a more stable core from which the
more easily dissociable components have already been removed during
preparation. Our findings that nuclei contain a larger, apparently more
stable complex suggest that the different sizes of complex obtained
from different sources and by different laboratories may, in fact, be
due to stability during isolation. It is particularly noteworthy that
in the nuclear system the tightly bound core synthetases are still
exclusively found in the complex, whereas those usually found as free
forms in the cytoplasm are found in the nucleus both in the large
complex and in intermediate-sized entities. However, almost no free
forms are seen. This argues strongly for partial breakdown of the
nuclear complex leading to partial removal of the more easily
dissociable synthetases. If this explanation is correct, it suggests
that the nuclear and cytoplasmic forms of the multienzyme complex may
be assembled into a similar organized structure.
This, of course, raises the interesting question of what might be the
function of a nuclear multienzyme aminoacyl-tRNA synthetase complex.
The simplest explanation is that these enzymes always remain associated
with each other in vivo, whether in the cytoplasm or the
nucleus, to carry out their function of aminoacylation. Aminoacyl-tRNA
is known to be channeled in vivo (3, 31), and the existence
of aminoacyl-tRNA synthetases in a multienzyme complex may facilitate
direct transfer of all aminoacyl-tRNAs to EF1.
Interestingly, EF1 is also present in the nucleus (15, 16), and very
recent work indicates that it also participates in nuclear to
cytoplasmic transport of tRNA (32). Thus, in this context, the
aminoacylation of tRNA and its transfer to EF1 in the nucleus could be
completely analogous to the process in the cytoplasm. Alternatively,
the multienzyme complex may itself function as a high efficiency tRNA
transport machine. In this case, newly synthesized aminoacyl-tRNA
synthetases would enter the nucleus, either as free enzymes that
assemble into a multienzyme complex or as a preformed complex.
Synthetases would then associate with their cognate tRNAs, and multiple
tRNAs and synthetases would be transported to the cytoplasm together,
perhaps in cooperation with exportin-t (21, 22) or EF1 (32). One
advantage of such a model would be to maintain a cytoplasmic ratio of
tRNA to cognate synthetase of 1:1 and would result in partial assembly
of the cytoplasmic translation apparatus already in the nucleus. If
this model were correct, the channeling of tRNA, known to occur in the
cytoplasm, would need to be extended to nuclear processes as well.
Current work clearly shows a role for aminoacyl-tRNA synthetases in
nuclear to cytoplasmic transport of tRNA (18-22). Whether this role is
limited only to proofreading by aminoacylation or whether there might
also be a role as an actual tRNA transporter remains to be determined.
 |
ACKNOWLEDGEMENT |
We thank Olena Shcherbyna-Hawks for excellent
technical assistance.
 |
FOOTNOTES |
*
This work was supported by Grant GM16317 from the National
Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 305-243-3150;
Fax: 305-243-3955; E-mail: mdeutsch@med.miami.edu.
Published, JBC Papers in Press, August 4, 2000, DOI 10.1074/jbc.C000385200
 |
ABBREVIATIONS |
The abbreviations used are:
EF1, elongation
factor 1;
CHO, Chinese hamster ovary;
PBS, phosphate-buffered
saline.
 |
REFERENCES |
| 1.
|
Ibba, M.,
Curnow, A. W.,
and Söll, D.
(1997)
Trends Biochem. Sci.
22,
39-42
|
| 2.
|
Negrutskii, B. S.,
Stapulionis, R.,
and Deutscher, M. P.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
964-968
|
| 3.
|
Stapulionis, R.,
and Deutscher, M. P.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7158-7161
|
| 4.
|
Bandyopadhyay, A. K.,
and Deutscher, M. P.
(1971)
J. Mol. Biol.
60,
113-122
|
| 5.
|
Mirande, M.
(1991)
Prog. Nucleic Acid Res.
40,
95-142
|
| 6.
|
Kisselev, L. L.,
and Wolfson, A. D.
(1994)
Prog. Nucleic Acid Res.
48,
83-142
|
| 7.
|
Yang, D. C. H.
(1996)
Curr. Top. Cell. Regul.
34,
101-136
|
| 8.
|
Filonenko, V. V.,
and Deutscher, M. P.
(1994)
J. Biol. Chem.
269,
17375-17378
|
| 9.
|
Quevillon, S.,
Robinson, J.-C.,
Berthonneau, E.,
Siatecka, M.,
and Mirande, M.
(1999)
J. Mol. Biol.
285,
183-195
|
| 10.
|
Rho, S. B.,
Kim, M. J.,
Lee, J. S.,
Seol, W.,
Motegi, H.,
Kim, S.,
and Shiba, K.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
4488-4493
|
| 11.
|
Amar-Costesec, A.,
and Turu, C.
(1989)
Biol. Cell
65,
21-28
|
| 12.
|
Hampel, A.,
and Enger, M. D.
(1973)
J. Mol. Biol.
79,
285-293
|
| 13.
|
Mirande, M.,
LeCorre, D.,
and Waller, J.-P.
(1985)
Eur. J. Biochem.
147,
281-289
|
| 14.
|
Popenko, V. I.,
Ivanova, J. L.,
Cherny, N. E.,
Filonenko, V. V.,
Beresten, S. F.,
Wolfson, A. D.,
and Kisselev, L. L.
(1994)
Eur. J. Cell Biol.
65,
60-69
|
| 15.
|
Barbarase, E.,
Koppel, D. E.,
Deutscher, M. P.,
Smith, C. L.,
Ainger, K.,
Morgan, F.,
and Carson, J. H.
(1995)
J. Cell Sci.
108,
2781-2790
|
| 16.
|
Sanders, J.,
Brandsma, M.,
Janssen, G. M. C.,
Dijk, J.,
and Möller, V.
(1996)
J. Cell Sci.
109,
1113-1117
|
| 17.
|
Schimmel, P.,
and Wang, C.-C.
(1999)
Trends Biochem. Sci.
24,
127-128
|
| 18.
|
Lund, E.,
and Dahlberg, J. E.
(1998)
Science
282,
2082-2085
|
| 19.
|
Sarkar, S.,
Azad, A. K.,
and Hopper, A. K.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
14366-14371
|
| 20.
|
Hopper, A. K.
(1998)
Science
282,
2003-2004
|
| 21.
|
Arts, G.-J.,
Kuersten, S.,
Romby, P.,
Ehresmann, B.,
and Mattaj, I. W.
(1998)
EMBO J.
17,
7430-7441
|
| 22.
|
Lipowsky, G.,
Bischoff, F. R.,
Tzaurralde, E.,
Kutay, U.,
Schäfer, S.,
Gross, H. J.,
Beier, H.,
and Görlich, D.
(1999)
RNA (N.Y.)
5,
539-549
|
| 23.
|
Greenberg, M. E.,
and Bender, T. P.
(1997)
in
Current Protocols in Molecular Biology
(Ausubel, F. M., ed), Vol. I
, pp. 4.10.6-4.10.10, John Wiley & Sons, Inc., New York
|
| 24.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685
|
| 25.
|
Flings, S. P.,
and Gregerson, D. S.
(1986)
Anal. Biochem.
155,
83-88
|
| 26.
|
Miramatsu, M.,
Smetana, K.,
and Busch, H.
(1963)
Cancer Res.
23,
510-518
|
| 27.
|
Deutscher, M. P.,
and Ni, R. C.
(1982)
J. Biol. Chem.
257,
6003-6006
|
| 28.
|
Vellekamp, G.,
Sihag, R. K.,
and Deutscher, M. P.
(1985)
J. Biol. Chem.
260,
9843-9847
|
| 29.
|
Negrutskii, B. S.,
Shalak, V. F.,
Kerjan, P.,
El'skaya, A. V.,
and Mirande, M.
(1999)
J. Biol. Chem.
274,
4545-4550
|
| 30.
|
Sivaram, P.,
and Deutscher, M. P.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
3665-3669
|
| 31.
|
Negrutskii, B. S.,
and Deutscher, M. P.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4991-4995
|
| 32.
|
Grosshans, H.,
Hurt, E.,
and Simas, G.
(2000)
Genes Dev.
14,
830-840
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. D. Cho, C. L. M. J. Verlinde, and A. M. Weiner
Reengineering CCA-adding enzymes to function as (U,G)- or dCdCdA-adding enzymes or poly(C,A) and poly(U,G) polymerases
PNAS,
January 2, 2007;
104(1):
54 - 59.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Ling, Y.-N. Yao, Y.-G. Zheng, H. Wei, L. Wang, X.-F. Wu, and E.-D. Wang
The C-terminal Appended Domain of Human Cytosolic Leucyl-tRNA Synthetase Is Indispensable in Its Interaction with Arginyl-tRNA Synthetase in the Multi-tRNA Synthetase Complex
J. Biol. Chem.,
October 14, 2005;
280(41):
34755 - 34763.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Smith, V. Bhaskar, J. Fernandez, and A. J. Courey
Drosophila Ulp1, a Nuclear Pore-associated SUMO Protease, Prevents Accumulation of Cytoplasmic SUMO Conjugates
J. Biol. Chem.,
October 15, 2004;
279(42):
43805 - 43814.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W. Lee, B. H. Cho, S. G. Park, and S. Kim
Aminoacyl-tRNA synthetase complexes: beyond translation
J. Cell Sci.,
September 1, 2004;
117(17):
3725 - 3734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Halwani, S. Cen, H. Javanbakht, J. Saadatmand, S. Kim, K. Shiba, and L. Kleiman
Cellular Distribution of Lysyl-tRNA Synthetase and Its Interaction with Gag during Human Immunodeficiency Virus Type 1 Assembly
J. Virol.,
July 15, 2004;
78(14):
7553 - 7564.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Wang, T. Sekiguchi, E. Noguchi, and T. Nishimoto
A Hamster Temperature-Sensitive Alanyl-tRNA Synthetase Mutant Causes Degradation of Cell-Cycle Related Proteins and Apoptosis
J. Biochem.,
January 1, 2004;
135(1):
7 - 16.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Steiner-Mosonyi, D. M. Leslie, H. Dehghani, J. D. Aitchison, and D. Mangroo
Utp8p Is an Essential Intranuclear Component of the Nuclear tRNA Export Machinery of Saccharomyces cerevisiae
J. Biol. Chem.,
August 22, 2003;
278(34):
32236 - 32245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Hopper and E. M. Phizicky
tRNA transfers to the limelight
Genes & Dev.,
January 15, 2003;
17(2):
162 - 180.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. NATHANSON, T. XIA, and M. P. DEUTSCHER
Nuclear protein synthesis: A re-evaluation
RNA,
January 1, 2003;
9(1):
9 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. Maquat
NASty effects on fibrillin pre-mRNA splicing: another case of ESE does it, but proposals for translation-dependent splice site choice live on
Genes & Dev.,
July 15, 2002;
16(14):
1743 - 1753.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Azad, D. R. Stanford, S. Sarkar, and A. K. Hopper
Role of Nuclear Pools of Aminoacyl-tRNA Synthetases in tRNA Nuclear Export
Mol. Biol. Cell,
May 1, 2001;
12(5):
1381 - 1392.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. Szymanski, M. A. Deniziak, and J. Barciszewski
Aminoacyl-tRNA synthetases database
Nucleic Acids Res.,
January 1, 2001;
29(1):
288 - 290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Deinert, F. Fasiolo, E. C. Hurt, and G. Simos
Arc1p Organizes the Yeast Aminoacyl-tRNA Synthetase Complex and Stabilizes Its Interaction with the Cognate tRNAs
J. Biol. Chem.,
February 16, 2001;
276(8):
6000 - 6008.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|